Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04920383 · ClinicalTrials.gov registry record · Phase 1
ALPN-202 With PD-1 Inhibition in Advanced Malignancies
A Phase 1 study, sponsored by Alpine Immune Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT04920383: Clinical Trial Phase 1 study, sponsored by Alpine Immune Sciences.
NCT04920383 is a Phase 1 study that was terminated before completion, run by Alpine Immune Sciences. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04920383, a Phase 1 study, was terminated before completion, sponsored by Alpine Immune Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma.
Primary Outcome
Incidence of DLTs
Interventions
- DRUG ALPN-202
- DRUG pembrolizumab KEYTRUDA®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 1 |
Why NCT04920383 stopped before completion
NCT04920383 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 2 interventions - of which ALPN-202 is the first listed.
NCT04920383 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04920383 about?
NCT04920383 is a clinical study titled "ALPN-202 With PD-1 Inhibition in Advanced Malignancies". This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma.
What is the current status of trial NCT04920383?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2021-06-22. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT04920383?
The interventions under investigation include: ALPN-202 (DRUG), pembrolizumab KEYTRUDA® (DRUG).
Who is sponsoring clinical trial NCT04920383?
This trial is sponsored by Alpine Immune Sciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04920383's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI